Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome.
Baldwin AG. et al, (2024), Journal of medicinal chemistry
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist
Balıkçı E. et al, (2024), Journal of Medicinal Chemistry, 67, 7245 - 7259
Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε.
de Souza Gama FH. et al, (2024), Journal of medicinal chemistry
Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.
Henderson SH. et al, (2024), European journal of medicinal chemistry, 269
Recent advances in the structural biology of tyrosine kinases.
Rygiel KA. and Elkins JM., (2023), Current opinion in structural biology, 82
Updated protein domain annotation of the PARP protein family sheds new light on biological function.
Suskiewicz MJ. et al, (2023), Nucleic acids research
Target 2035 – an update on private sector contributions
Ackloo S. et al, (2023), RSC Medicinal Chemistry, 14, 1002 - 1011
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
Collins R. et al, (2022), J Med Chem
Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery.
Scott F. et al, (2022), Bioorganic & medicinal chemistry letters, 60
Chemical Probes for Understudied Kinases: Challenges and Opportunities.
Serafim RAM. et al, (2021), Journal of medicinal chemistry
Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
Serafim RAM. et al, (2021), Journal of medicinal chemistry
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Henderson SH. et al, (2021), Journal of medicinal chemistry, 64, 11709 - 11728
Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2.
Berger B-T. et al, (2021), Cell chemical biology, 28, 686 - 698.e7
Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
Quevedo CE. et al, (2020), Bioorganic & medicinal chemistry, 28
Mining Public Domain Data to Develop Selective DYRK1A Inhibitors.
Henderson SH. et al, (2020), ACS medicinal chemistry letters, 11, 1620 - 1626
Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors.
Asquith CRM. et al, (2020), ChemMedChem, 15, 1200 - 1215
Development of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer.
Scott F. et al, (2020), Bioorganic & medicinal chemistry letters, 30
SGC-AAK1-1: A Chemical Probe Targeting AAK1 and BMP2K.
Wells C. et al, (2020), ACS medicinal chemistry letters, 11, 340 - 345
Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships.
Asquith CRM. et al, (2020), ChemMedChem, 15, 26 - 49